NewAmsterdam Pharma Co N.V. - 10-Q Summary (Q3 2025)
Business Context and Reporting Period
NewAmsterdam Pharma Company N.V. is a late-stage biopharmaceutical company focused on developing obicetrapib, an oral CETP inhibitor for lowering LDL-C. This report covers the quarterly period ended September 30, 2025. The company operates as a single segment and relies on a strategic partnership with A. Menarini International Licensing S.A. for commercialization in Europe. As of September 30, 2025, the company had 113.2 million ordinary shares outstanding.
Key Financial Metrics
| Metric (in thousands USD) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Revenue | $348 | $29,111 | $22,471 | $32,791 |
| Net Loss | $(72,005) | $(16,647) | $(128,896) | $(149,421) |
| Operating Loss | $(55,143) | $(25,003) | $(159,703) | $(133,060) |
| Interest Income | $6,713 | $4,443 | $21,119 | $12,396 |
| Cash & Equivalents | $538,407 | $771,743 | As of Sept 30, 2025 | |
| Marketable Securities | $217,630 | $62,447 | As of Sept 30, 2025 | |
| Total Liquidity | $756.0 million (Cash + Marketable Securities) |
Material Changes vs. Prior Period
- Revenue Decline: Q3 2025 revenue dropped 99% to $0.3 million compared to $29.1 million in Q3 2024. This is primarily due to the recognition of a $27.3 million clinical development milestone in the prior year, which did not recur in the current quarter. The 9M 2025 revenue decreased 31% to $22.5 million, partially offset by $16.1 million in recognized R&D cost reimbursements from Menarini.
- Increased Net Loss: Q3 2025 net loss widened to $72.0 million from $16.6 million in Q3 2024. The increase was driven by a $23.8 million loss from the fair value change of warrant liabilities and higher SG&A expenses. Conversely, the 9M 2025 net loss improved to $128.9 million from $149.4 million in 9M 2024, aided by a $13.1 million foreign exchange gain and reduced clinical expenses.
- Expense Trends: R&D expenses decreased 13% in Q3 and 11% in 9M 2025, driven by the completion of several Phase 3 trials. SG&A expenses increased 33% in Q3 and 60% in 9M 2025, largely due to increased personnel costs and share-based compensation ($15.4 million increase in 9M) related to commercial preparedness.
- Liquidity Position: Cash and cash equivalents decreased from $771.7 million to $538.4 million during the quarter. However, total liquidity remains robust at $756.0 million due to significant investments in marketable securities ($217.6 million).
Guidance, Outlook, and Risks
- Regulatory Milestones: In August 2025, the European Medicines Agency (EMA) validated Marketing Authorization Applications (MAAs) for obicetrapib monotherapy and fixed-dose combination. The company expects to commercialize in the U.S. independently and is evaluating partners for other regions.
- Clinical Trials: The PREVAIL cardiovascular outcomes trial (CVOT) completed enrollment in April 2024. The trial is expected to conclude no earlier than the end of 2026, pending the occurrence of the target number of Major Adverse Cardiovascular Events (MACE).
- Supply Agreement: A new supply agreement with Menarini was signed in August 2025, establishing NewAmsterdam as the exclusive supplier of drug products for European distribution, with pricing based on a markup of cost of goods sold.
- Risks:
- Regulatory & Pricing: Potential impacts from U.S. healthcare reform, including the Inflation Reduction Act (IRA) and new executive orders regarding "Most-Favored-Nation" pricing, could limit future reimbursement and pricing power.
- Trade Policy: New tariffs imposed by the U.S. administration on imports, including a 100% tariff on certain branded pharmaceuticals announced in September 2025, pose risks to supply chain costs and global trade.
- Capital Needs: The company expects to continue incurring significant losses and will require additional capital to fund operations and commercialization.
Investor Verification Checklist
- Revenue Sustainability: Verify the timeline for future milestone payments and the volume of product supply revenue under the new Menarini agreement, given the absence of large milestone recognitions in Q3 2025.
- Warrant Liability Volatility: Monitor the fair value of derivative warrant liabilities ($44.4 million), which significantly impacts net loss and is highly sensitive to the company's stock price.
- Cash Burn Rate: Assess the runway provided by the $756 million liquidity position against the current operating cash burn of approximately $107 million for the nine-month period.
- Regulatory Approval: Track the status of the EMA review process for the validated MAAs and the timeline for the PREVAIL CVOT results.
- Share-Based Compensation: Review the impact of increasing share-based compensation expenses ($45.4 million in 9M 2025) on future profitability and dilution.